Evidence map›Paper›PMID 27642141›Full record

ArticleHepatology (Baltimore, Md.)2017

Hepatitis C virus double-stranded RNA is the predominant form in human liver and in interferon-treated cells.

Arielle Klepper, Francis J Eng, Erin H Doyle, Ahmed El-Shamy, Adeeb H Rahman, M Isabel Fiel, Gonzalo Carrasco Avino, Moonju Lee, Fei Ye, Sasan Roayaie and 4 more

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Hepatology (Baltimore, Md.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. [Histological evaluation of liver in chronic hepatitis C after direct-acting antiviral agents treatment].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Arielle KlepperIcahn School of Medicine at Mount Sinai, New York, NY.
Francis J EngIcahn School of Medicine at Mount Sinai, New York, NY.
Erin H DoyleIcahn School of Medicine at Mount Sinai, New York, NY.
Ahmed El-ShamyIcahn School of Medicine at Mount Sinai, New York, NY.
Adeeb H RahmanIcahn School of Medicine at Mount Sinai, New York, NY.
M Isabel FielIcahn School of Medicine at Mount Sinai, New York, NY.
Gonzalo Carrasco AvinoIcahn School of Medicine at Mount Sinai, New York, NY.
Moonju LeeIcahn School of Medicine at Mount Sinai, New York, NY.
Fei YeIcahn School of Medicine at Mount Sinai, New York, NY.
Sasan RoayaieIcahn School of Medicine at Mount Sinai, New York, NY.
Meena B BansalIcahn School of Medicine at Mount Sinai, New York, NY.
Margaret R MacDonaldThe Rockefeller University, Laboratory of Virology and Infectious Disease, New York, NY.
Thomas D SchianoIcahn School of Medicine at Mount Sinai, New York, NY.
Andrea D BranchIcahn School of Medicine at Mount Sinai, New York, NY.
Icahn School of Medicine at Mount Sinai · USRockefeller University · US

Funding

Post-Baccalaureate Research Education Program (PREP)R25GM064118 · NIGMS · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI CAMPBELL, KIRK N, SLY, JAMILIA RAKI · 2001 to 2024
$7.2M
Optimizing Vitamin D Treatment in HIV/AIDS: An RCTR01DA031095 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BRANCH, ANDREA D., DIETERICH, DOUGLAS THOMAS · 2010 to 2014
$3.3M
TRAINING PROGRAM IN INVESTIGATIVE GASTROENTEROLOGYT32DK007792 · NIDDK · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI CHO, JUDY H. · 2001 to 2016
$2.3M
Clinical Outcomes and the HCV Core GeneR01DK090317 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BRANCH, ANDREA D. · 2010 to 2014
$2.0M
HCV Strain Variation and HCCR21CA152514 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BRANCH, ANDREA D. · 2011 to 2012
$406k
A Novel Cultue System for Hepatitis C VirusF31AI081530 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KLEPPER, ARIELLE · 2009 to 2010
$83k
NCI NIH HHS R21 CA152514NIAID NIH HHS F31 AI081530NIDA NIH HHS R01 DA031095NIDDK NIH HHS DK00779211NIDDK NIH HHS DK09031702NIDDK NIH HHS R01 DK090317NIDDK NIH HHS T32 DK007792NIGMS NIH HHS R25 GM064118
6 · The paper itself

Abstract

Hepatitis C virus (HCV) is unique among RNA viruses in its ability to establish chronic infection in the majority of exposed adults. HCV persists in the liver despite interferon (IFN)-stimulated gene (ISG) induction; robust induction actually predicts treatment failure and viral persistence. It is unclear which forms of HCV RNA are associated with ISG induction and IFN resistance during natural infections. To thoroughly delineate HCV RNA populations, we developed conditions that fully separate the strands of long double-stranded RNA (dsRNA) and allow the released RNAs to be quantified in reverse transcription/polymerase chain reaction assays. These methods revealed that dsRNA, a pathogen-associated molecular pattern (PAMP), comprised 52% (standard deviation, 28%) of the HCV RNA in the livers of patients with chronic infection. HCV dsRNA was proportionally higher in patients with the unfavorable IL28B TT (rs12979860) genotype. Higher ratios of HCV double-stranded to single-stranded RNA (ssRNA) correlated positively with ISG induction. In Huh-7.5 cells, IFN treatment increased the total amount of HCV dsRNA through a process that required de novo viral RNA synthesis and shifted the ratio of viral dsRNA/ssRNA in favor of dsRNA. This shift was blocked by ribavirin (RBV), an antiviral drug that reduces relapse in HCV patients. Northern blotting established that HCV dsRNA contained genome-length minus strands.

conclusionHCV dsRNA is the predominant form in the HCV-infected liver and has features of both a PAMP and a genomic reservoir. Interferon treatment increased rather than decreased HCV dsRNA. This unexpected finding suggests that HCV produces dsRNA in response to IFN, potentially to antagonize antiviral defenses. (Hepatology 2017;66:357-370).

Indexed as

AdultAntiviral AgentsBiopsy, NeedleBlotting, WesternCells, CulturedFemaleFlow CytometryHepacivirusHepatitis CHepatocytesHumansImmunohistochemistryInterferon-alphaMaleReference ValuesRNA, Double-StrandedAntiviral AgentsInterferon-alphaRNA, Double-StrandedRNA, Viral

Identifiers

PMID27642141
PMCPMC5573989
OpenAlexW2523033164

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.